Novartis to Acquire Myricx Bio for Up to $1.5 Billion to Advance Next-Generation Cancer Therapies
Swiss drugmaker Novartis has announced that it will acquire UK-based biotechnology company Myricx Bio in a deal that values up to $1.5 billion. This indicates that Novartis is completely focused on developing innovative cancer treatments and also in strengthening its oncology pipeline through cutting-edge technologies.
This deal will help the company fasten the development of targeted therapies for the patients with the cancers that are difficult to treat.
A Deal Worth Up to $1.5 Billion
Under this agreement, Novartis said it would pay $1.1 billion upfront, alongside up to $400 million in potential milestone payments, to acquire London-based Myricx Bio, which develops antibody-drug conjugates used for treating cancer.
Why Myricx Bio?
Myricx Bio is a UK based biotechnology company co-founded as a joint spinout with the Francis Crick Institute, with vital initial funding and tracking from Sofinnova Partners and Brandon Capital, that has gained attention for developing a new class of cancer therapies based on N-myristoyltransferase (NMT) inhibitors.
N-myristoyltransferase is an enzyme responsible for lipid modifications essential for protein scaffolding, signaling, and survival within cancer cells.
Although Myricx Bio doesn’t have any approved products yet, its early-stage research (these assets are entirely preclinical) has attracted strong interest from investors like Novo Holdings, as its pipeline explicitly targets solid tumors, with its two lead antibody-drug conjugate (ADC) assets directed against B7-H3 and HER2.
Strengthening Novartis’ Cancer Drug Pipeline
The acquisition also gives Novartis access to Myricx Bio’s innovative work in antibody-drug conjugates (ADCs).
“ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients,” said Fiona Marshall, president of biomedical research at Novartis.
“This proposed acquisition reflects our strategy to scale innovative platforms, as we have with radioligand therapies, to deliver more durable, transformative treatments for patients.”
Myricx Bio has developed a novel ADC payload technology that could improve the effectiveness of future cancer treatments. By combining this technology with its own research capabilities, Novartis hopes to develop safer and more effective therapies for patients worldwide.
Part of Novartis’ Long-Term Oncology Strategy
Novartis has been actively investing in advanced cancer treatment technologies over the past few years. The company has expanded its portfolio in areas like radioligand therapies, cell and gene therapies, and antibody-drug conjugates.
The addition of Myricx Bio further strengthens its early-stage oncology research pipeline and supports its long-term strategy of bringing innovative medicines to patients.
The acquisition also reflects a growing trend in the pharmaceutical industry, where large drug makers are acquiring smaller biotech companies with promising research platforms instead of building every technology internally.
Many industry experts believe antibody-drug conjugates and targeted therapies will play a major role in the future of cancer treatment.
A Major Milestone for Myricx Bio
For Myricx Bio, the acquisition marks an important milestone in its journey from a university spinout to becoming part of one of the world’s largest pharmaceutical companies. With Novartis’ global research network, development expertise, and financial resources, Myricx Bio’s experimental therapies will have greater opportunities to move through clinical development and reach patients.
The deal is also a significant achievement for Imperial College London and Novo Holdings, both of which supported the company’s growth from its early stages.
